United StatesBreaking News

Palvella Therapeutics (NASDAQ:PVLA) said it has submitted the first module of a rolling New Drug Application to the U.S. Food and Drug Administration for QTORIN 3.9% rapamycin gel.

iHuman (NYSE:IH) reported first-quarter 2026 revenue of RMB182.5 million, compared with RMB210.4 million in the same period last year, showing a year-over-year decline.

Comcast (NASDAQ:CMCSA) said it will divide its operations into two standalone public companies, separating its media assets from its connectivity and technology businesses through a tax-free spin-off.

BrainsWay (NASDAQ:BWAY) reported positive real-world data from what it described as the largest analysis of Deep Transcranial Magnetic Stimulation in patients with comorbid post-traumatic stress disorder and major depressive disorder.

Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.

Alicia Levine, chief investment officer at BNY Wealth, expects an upswing in volatility over the next few months, but sees a broadening of earnings driving the S&P 500 to 8,000 by the end of the year.

Roadzen (NASDAQ:RDZN) reported its best quarter and fiscal year with fourth quarter revenue of $16.1 million, up 42% year over year and 12% sequentially.

Tonix Pharmaceuticals (NASDAQ:TNXP) said it enrolled the first patient in HORIZON, a Phase 2, randomized, double-blind, placebo-controlled study of TNX-102 SL 5.6 mg for adults with major depressive disorder.

HP (NYSE:HPQ) announced a strategic partnership with OpenAI to deploy its Frontier enterprise AI platform across HP’s global business operations.

Artivion (NYSE:AORT) announced that the U.S. Food and Drug Administration has granted premarket approval for its AMDS Hybrid Prosthesis for the treatment of acute DeBakey Type I aortic dissections with malperfusion.

Helus Pharma (NASDAQ:HELP) reported fiscal 2026 results with cash of $157.3 million as of March 31, 2026.

Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.